Case Report: Toxic Epidermal Necrolysis Induced by Tislelizumab in a Patient with Esophageal Squamous Cell Carcinoma

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2025 Jan 7

PMID 39764552

Authors

Shilong Wu

Chenyang Xu

Huafeng Liu

Affiliations

Soon will be listed here.

Abstract

Background: Immune checkpoint inhibitors (ICIs) have been widely applicated for the treatment of patients with advanced esophageal cancer. Skin-related adverse reactions are frequent with ICIs, with toxic epidermal necrolysis (TEN) being a severe and potentially life-threatening cutaneous reaction.

Case Presentation: We present a case of a 70-year-old male with locally advanced esophageal cancer who developed severe toxic epidermal necrolysis (TEN) after 18 days of tislelizumab combined with chemotherapy. The condition rapidly progressed to cover approximately 90% of his body. After treatment with intravenous methylprednisolone, immunoglobulin, and antibiotics, along with active nutritional support and wound care, the patient recovered from TEN induced by tislelizumab.

Conclusion: Treatment for TEN is complex, and no standardized guidelines currently exist. We propose an economical, safe, effective, and simple strategy for similar TEN patients.

References

Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau J, Revuz J, Wolkenstein P . SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000; 115(2):149-53. DOI: 10.1046/j.1523-1747.2000.00061.x. View

Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K . ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010; 88(1):60-8. DOI: 10.1038/clpt.2009.252. View

Marks M, Botta R, Abe R, Beachkofsky T, Boothman I, Carleton B . Updates in SJS/TEN: collaboration, innovation, and community. Front Med (Lausanne). 2023; 10:1213889. PMC: 10600400. DOI: 10.3389/fmed.2023.1213889. View

Enescu C, Elder A, Deirawan H, Moossavi M . To Debride or Not to Debride: A Review of Wound Management for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Cureus. 2024; 16(3):e55350. PMC: 10981949. DOI: 10.7759/cureus.55350. View

Fick C, Dunne E, Sihag S, Molena D, Cytryn S, Janjigian Y . Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma. Ann Thorac Surg. 2024; 118(1):130-140. PMC: 11194153. DOI: 10.1016/j.athoracsur.2024.02.021. View

Xu J, Kato K, Raymond E, Hubner R, Shu Y, Pan Y . Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023; 24(5):483-495. DOI: 10.1016/S1470-2045(23)00108-0. View

Bastuji-Garin S, Rzany B, Stern R, Shear N, Naldi L, Roujeau J . Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993; 129(1):92-6. View

Geisler A, Phillips G, Barrios D, Wu J, Leung D, Moy A . Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020; 83(5):1255-1268. PMC: 7572894. DOI: 10.1016/j.jaad.2020.03.132. View

Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C . Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(12):1217-1238. DOI: 10.1016/j.annonc.2022.10.001. View

10.

Wasuwanich P, So J, Chakrala T, Chen J, Motaparthi K . Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome. JAAD Int. 2023; 13:17-25. PMC: 10413346. DOI: 10.1016/j.jdin.2023.06.014. View

11.

Zhou J, Wang C, Li J, Zhang H, He C . Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review. Front Immunol. 2024; 15:1414136. PMC: 11272453. DOI: 10.3389/fimmu.2024.1414136. View

12.

Heng Y, Lee H, Roujeau J . Epidermal necrolysis: 60 years of errors and advances. Br J Dermatol. 2016; 173(5):1250-4. DOI: 10.1111/bjd.13989. View

13.

Shoji Y, Koyanagi K, Kanamori K, Tajima K, Ogimi M, Ninomiya Y . Immunotherapy for esophageal cancer: Where are we now and where can we go. World J Gastroenterol. 2024; 30(19):2496-2501. PMC: 11135418. DOI: 10.3748/wjg.v30.i19.2496. View

14.

Zheng J, Huang B, Xiao L, Wu M, Li J . Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials. Front Oncol. 2022; 12:821626. PMC: 9780048. DOI: 10.3389/fonc.2022.821626. View

15.

Thompson J, Schneider B, Brahmer J, Andrews S, Armand P, Bhatia S . Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019; 17(3):255-289. DOI: 10.6004/jnccn.2019.0013. View

16.

Waters J, Reznik S . Update on Management of Squamous Cell Esophageal Cancer. Curr Oncol Rep. 2022; 24(3):375-385. DOI: 10.1007/s11912-021-01153-4. View

17.

Qin K, Gong T, Ruan S, Lin M, Su X, Lv X . Clinical Features of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor versus Non-Immune Checkpoint Inhibitor Drugs in China: A Cross-Sectional Study and Literature Review. J Inflamm Res. 2024; 17:7591-7605. PMC: 11512543. DOI: 10.2147/JIR.S491791. View

18.

Maloney N, Ravi V, Cheng K, Bach D, Worswick S . Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol. 2020; 59(6):e183-e188. DOI: 10.1111/ijd.14811. View